CytomX Therapeutics (STU:6C1) Total Long-Term Liabilities : €66.1 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. CytomX Therapeutics's Total Long-Term Liabilities for the quarter that ended in Mar. 2024 was €66.1 Mil.

CytomX Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for CytomX Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Total Long-Term Liabilities Chart

CytomX Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Liabilities

Get a 7-Day Free Trial

184.12

245.22

231.87

183.17

85.58

CytomX Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Long-Term Liabilities	Get a 7-Day Free Trial															158.78	141.07	117.70	85.58	66.09

CytomX Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

CytomX Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics (STU:6C1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics (STU:6C1) Headlines

No Headlines